natgillin/translations-raw huggingface dataset:
Of the patients who achieved at least a 20% reduction of parenteral nutrition at Weeks 20 and 24 in the initial study, 75% sustained this response on Revestive after up to 1 year of continuous treatment.
75%-l patsientidest, kes saavutasid nädalatel 20 ja 24 vähemalt 20%-lise parenteraalse toitmise vähenemise, püsis see toime ka kuni 1-aastase raviperioodi vältel.
Of the patients who achieved CCyR, 85% (95% CI: 78% - 93%) were maintaining response at 24 months.
CCyR’i (täieliku tsütogeneetilise ravivastuse) saavutanud patsientidest 85% (95% CI: 78...93%) säilis ravivastus 24 kuu möödudes.
Of the patients who achieved HR, 53% (95% CI: 39% - 67%) were maintaining response at 24 months.
HR’i saavutanud patsientidest 53% (95% CI: 39...67%) säilis ravivastus 24 kuu möödudes.
Of the patients who achieved MCyR, 63% (95% CI: 45% - 80%) were maintaining response at 24 months.
MCyR’i saavutanud patsientidest 63% (95% CI: 45...80%) säilis ravivastus 24 kuu möödudes.
Of the patients who achieved MCyR, 77% (95% CI: 70% - 84%) were maintaining response at 24 months.
MCyR’i saavutanud patsientidest 77% (95% CI: 70...84%) säilis ravivastus 24 kuu möödudes.
Of the patients who did not convert to sinus rhythm, the incidence of bradycardia events in the first 2 hours post-dose was similar in placebo and vernakalant treated groups (4.0% and 3.8%, respectively).
Patsientide seas, kellel siinusrütm ei taastunud, oli bradükardia episoodide esinemissagedus esimese 2 tunni jooksul pärast ravimi manustamist sarnane platseebo- ja vernakalandi rühmades (vastavalt 4,0% ja 3,8%).
Of the patients who did not meet stability criteria for the individual components, 12 of 15 Cerdelga patients and 3 of 3 Cerezyme patients remained within therapeutic goals for GD1.
Patsientidest, kes üksikkomponentide osas stabiilsuse kriteeriume ei saavutanud, püsisid 1. tüüpi Gaucher’ tõve ravieesmärkide raames 12 patsienti 15-st Cerdelga rühma patsiendist ja 3 patsienti 3-st Cerezyme’i rühma patsiendist.
Of the patients who had been clinically diagnosed with MCI at study entry, 9 (19%) converted to clinical AD 36 months later.
Patsientidest, kellel uuringusse kaasamisel oli kliiniliselt diagnoositud MCI, muutus 9 patsiendil (19 %) 36 kuu pärast seisund kliiniliseks AD’ks.
Of the patients who had been clinically diagnosed with MCI at study entry, 9 (19%) converted to clinical AD 36 months later.
Patsientidest, kellel uuringusse kaasamisel oli kliiniliselt diagnoositud MCI, muutus 9 patsiendil (19%) 36 kuu pärast seisund kliiniliseks AD’ks.
Of the patients who lost adequate response after re-randomization to placebo who then enrolled into the open-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively.
Kõigist patsientidest, kellel pärast platseebole rerandomiseerimist kadus piisav ravivastus ja kes seejärel kaasati avatud jätku-uuringusse, saavutasid PASI 75 ravivastuse 12 ja 24 nädalat pärast korduva ravi alustamist vastavalt 38% (25/66) ja 55% (36/66).
Of the patients who lost adequate response after re-randomization to placebo who then enrolled into the open-label extension trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, respectively.
Kõikidest patsientidest, kellel kadus adekvaatne ravivastus pärast re-randomisatsiooni platseebole ülemineku tõttu, osalesid avatud jätku-uuringus 38% (25/66) ja 55% (36/66) saavutasid PASI 75 tulemuse vastavalt pärast 12 ja 24 nädalat kestnud korduvravikuuri.
Of the patients who received nivolumab, the ORR in the BRAF mutation-positive subgroup (n=26) was 23% (95% CI: 9.0, 43.6), and 34% (95% CI: 24.6, 44.5) in patients whose tumours were BRAF wild-type (n=94).
Nivolumabi saanud BRAF positiivse mutatsiooniga patsientide alamrühmas (n=26) oli objektiivse ravivastuse määr 23% (95% usalduspiirid: 9,0; 43,6) ja metsikut tüüpi BRAF kasvajatega patsientide alarühmas (n=94) 34% (95% usalduspiirid: 24,6; 44,5).
Of the patients who received Simponi, 51% (74 out of 146) had 20% reductions after 14 weeks, compared with 9% of patients who were given placebo (10 out of 113).
Simponi rühmas oli patsiente, kelle sümptomid vähenesid 20% 14 nädala järel, 51% (74 patsienti 146st) ja platseeborühmas 9% (10 patsienti 113st).
Of the patients who received Simponi, 59% (82 out of 138) had 20% reductions after 14 weeks, compared with 22% of patients who were given placebo (17 out of 78).
Simponi rühmas oli patsiente, kelle sümptomid vähenesid 20% 14 nädala järel, 59% (82 patsienti 138st) ja platseeborühmas 22% (17 patsienti 78st).
Of the patients who received Simponi, 71% (69 out of 97) had 20% reductions after 16 weeks, compared with 40% of patients who were given placebo (40 out of 100).
Simponi rühmas oli patsiente, kelle sümptomid vähenesid 20% 16 nädala järel, 71% (69 patsienti 97st) ja platseeborühmas 40% (40 patsienti 100st).
Of the patients with at least a PASI-50 response who were re-randomized to placebo at Week 32, 24.2% were PASI-50 responders at Week 52.
24,2% patsientidest, kellel oli tekkinud vähemalt PASI-50 ravivastus ja kes 32. nädalal kordusrandomiseeriti platseeborühma, oli 52. nädalal PASI-50 ravivastus.
Of the patients with at least a PASI-75 response who were re-randomized to placebo at Week 32 during a Randomized Treatment Withdrawal Phase, 11.7% were PASI-75 responders at Week 52.
11,7% patsientidest, kellel oli tekkinud vähemalt PASI-75 ravivastus ja kes 32. nädalal randomiseeritud ravi lõpetamise faasis kordusrandomiseeriti platseeborühma, oli 52. nädalal PASI-75 ravivastus.
Of the patients with treatment interrupted due to peripheral neuropathy, 44% (31/70 patients) were able to resume Abraxane at a reduced dose.
Perifeerse neuropaatia tõttu ravi katkestanud patsientidest oli 44% (31 patsienti 70-st) võimalik jätkata ravi Abraxane’i vähendatud annusega.
of the plasma levels of saquinavir is
oovitatakse tingimata jälgida
of the plasma levels of saquinavir is
tingimata jälgida lopinaviiri taset
Of the randomised patients, 44.9 % had a complete/partial response and 51.9 % had a response of stable disease to pemetrexed plus cisplatin induction.
Pemetrekseed + tsisplatiini induktsioonravile randomiseeritud patsientidest saavutas 44,9% täieliku/osalise ravivastuse ning 51,9% patsientidest saavutas ravivastusena haiguse stabiliseerumise.
OF THE REACH AND SIGHT OF CHILDREN
KÄTTESAAMATUS KOHAS
of the reductions in
farmakokineetiliste näitajate
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (≥ 1:40) was higher in patients treated with etanercept (11%) than in placebo- treated patients (5%).
Reumatoidartriidiga patsientidel, kellel uuriti antinukleaarsete antikehade esinemist (ANA), muutus ANA-test positiivseks (≥ 1:40) sagedamini etanertseptiga ravitud patsientidel (11%) kui platseeboga ravitud patsientidel (5%).
Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).
Nendest reumatoidartriidiga patsientidest, kellel uuriti antinukleaarsete antikehade esinemist (ANA), muutus ANA-test positiivseks (≥1:40) suuremal hulgal Enbreliga ravitud patsientidest (11%), võrreldes platseeboga ravitud patsientide arvuga (5%).
Of the serious adverse events (SAEs) in the PhotoBarr PDT + OM group, 44 (23.1%) were considered associated with the treatment.
Tõsistest kõrvaltoimetest loeti PhotoBarr’i PDT+OM grupis 44 (23,1%) raviga seotud olevat.
OF THE SIGHT AND REACH OF CHILDREN
ERIHOIATUS, ET RAVIMIT TULEB HOIDA LASTE EEST VARJATUD JA KÄTTESAAMATUS KOHAS
OF THE SIGHT AND REACH OF CHILDREN
KÄTTESAAMATUS KOHAS
Of the specimens from the non-clinical and clinical studies (n = 876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Mittekliinilistest ja kliinilistest uuringutest saadud proovide põhjal (n = 876), mis olid THxID BRAF analüüsi põhjal mutatsiooni suhtes positiivsed ja mida lisaks analüüsiti ka referentsmeetodi ehk sekveneerimise teel, oli analüüsi spetsiifilisus 94%.
Of the specimens from the non-clinical and clinical studies (n=876) that were mutation positive by the THxID BRAF assay and subsequently were sequenced using the reference method, the specificity of the assay was 94%.
Mittekliinilistest ja kliinilistest uuringutest saadud proovide põhjal (n=876), mis olid THxID BRAF analüüsi põhjal mutatsiooni suhtes positiivsed ja mida lisaks analüüsiti ka referentsmeetodi ehk sekveneerimise teel, oli analüüsi spetsiifilisus 94%.
Of the subjects who received primary infant series of Bexsero, 3285 received a booster dose in the second year of life.
3285-le katsealusele, kellele manustati imikuna esmase immuniseerimise käigus Bexsero vaktsiini, süstiti teisel eluaastal kordusannus.
Of the subjects with observed data at Week 16 in the four Phase 3 clinical trials, 50.8% of those randomized to receive naltrexone / bupropion had lost ≥5% of their baseline body weight, compared to 19.3% of placebo-treated subjects (Week 16 Responders).
Neljas III faasi kliinilises uuringus osalejatest, kellel avaldusid 16. nädalal ravitulemused, kaotas 50,8% naltreksoon/bupropioonirühma randomiseeritutest ≥ 5% ravieelsest kehakaalust võrreldes 19,3% platseeborühmas osalenutest (ravivastusega 16. nädalal).
Of the total 123 patients, 26 patients died; each of these deaths could be attributed either as a complication of the index event or associated with co-morbidities.
123-st patsiendist 26 surid; kõigil juhtudel oli surma põhjuseks kas põhihaiguse tüsistused või kaasuvad haigused.
Of the total 128 patients who entered part I taking corticosteroids, 92 attempted corticosteroid tapering.
Uuringu I ossa kaasatud patsientidest kasutas kortikosteroide kokku 128 patsienti, 92 proovisid vähendada kortikosteroidi annust.
Of the total 25 subjects: 9 received placebo, 9 received mepolizumab 75 mg intravenously, and 7 received 100 mg subcutaneously.
Kokku 25 uuringualusest 9 said platseebot, 9 75 mg mepolizumabi intravenoosselt ja 7 100 mg subkutaanselt.
Of the total number of patients in clinical studies of dabrafenib (N=578), 22% were 65 years of age and older, and 6% were 75 years of age and older.
Dabrafeniibi kliinilistes uuringutes osalenud patsientidest (N=578) 22% olid 65-aastased ja vanemad ning 6% olid 75-aastased ja vanemad.
Of the total number of patients in clinical studies of osimertinib (N=411), 46% were 65 years of age and older, of whom 13% were 75 years of age and older.
Osimertiniibi kliinilistes uuringutes osalenud kõigist patsientidest (n=411) olid 46% 65-aastased ja vanemad, kellest 13% olid 75-aastased ja vanemad.
Of the total number of patients with CTCL in clinical studies, 61% were 60 years or older, while 30% were 70 years or older.
Kliinilistes uuringutes osalenud naha T-rakulise lümfoomiga patsientide koguarvust olid 61% 60- aastased või vanemad ja 30% olid 70-aastased või vanemad.
Of the total number of subjects in clinical studies of Velphoro, 29.7 % were aged 65 and over, while 8.7% were aged 75 and over.
Velphoro kliinilistes uuringutes oli 29,7% uuritavatest 65-aastased ja vanemad ning 8,7% 75-aastased ja vanemad.
Of them, all reported vascular elbow lesions, but also neurologic symptoms (1 case), bone and muscle pain (2 cases), and skin striae (2 cases).
Neist kõik kaebasid vaskulaarsete küünarnukikahjustuste üle, samuti esines neil ka neuroloogilisi sümptomeid (1 juhtum), luu- ja lihasvalu (2 juhtumit) ning nahastriiad (2 juhtumit).
Of these 15 patients with unmet medical need who had received prior imatinib only, patients had a response on Bosulif treatment of MCyR or better, including 3 patients with CMR, 1 patient with MMR, 4 patients with CCyR, and 1 patients with PCyR with a duration of MCyR ranging from 12 to 155 weeks and a treatment duration ranging from 24 to 197+ weeks.
Neist 15-st täiendavat ravi vajavast patsiendist, kes olid varem saanud ainult imatiniibi, esines üheksal patsiendil MCyR või parem vastus Bosulifiga teostatud ravile, sealhulgas kolm patsienti CMR-iga, üks patsient MMR-iga, neli patsienti CCyR-iga ja üks patsient PCyR-iga.
Of these 17 patients, there were 5 patients who discontinued treatment.
Neist 17 patsiendis 5 lõpetas ravi.
Of these 19 patients 11 were infected with methicillin-susceptible and 8 with methicillin-resistant Staphylococcus aureus.
Sellest 19 patsiendist olid 11 infitseerunud metitsilliinitundliku Staphylococcus aureus-ega ja 8 metitsilliinresistentse Staphylococcus aureus-ega.
Of these 2 cases of torsade de pointes with positive dechallenge after dose reduction or discontinuation of rivastigmine, the causal role of rivastigmine due to its bradycardia-related adverse event could not be ruled out despite the confounding factors in these cases (venlafaxine, tiapride).
Kuna nende 2 torsade de pointes juhu korral taandus kõrvaltoime pärast rivastigmiini annuse vähendamist või rivastigmiinravi lõpetamist (positive dechallenge), ei saa seost rivastigmiini kasutamise ja bradükardiaga seotud kõrvaltoime tekke vahel välistada hoolimata hindamist segavate faktorite (venlafaksiini, tiapriidi kasutamine samaaegselt) olemasolust.
Of these 24 cases, a description of the scar was available for 13 and the majority described redness (5 cases), pigmentation changes (5 cases) or hypertrophy (2 cases).
Lisaks on turustamisjärgselt teatatud pigmentatsiooni muutustest, sealhulgas nii hüpo- kui ka hüperpigmentatsioonist pärast ingenoolmebutaadi kasutamist.
Of these 34 patients, none experienced severe (NCI-CTCAE Grade 4) infusion or hypersensitivity reactions (anaphylaxis) that were clearly related to ATA.
Nendest 34 patsiendist mitte ühelgi ei tekkinud raskeid (NCI-CTCAE 4. raskusastme) infusiooni- või ülitundlikkusreaktsioone (anafülaksia), mis olid kindlasti seotud ATAdega.
Of these 41 patients, 29 presented with disorders in primary bile acid synthesis including Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency (n=4).
Neist 41 patsiendist 29-l olid esmaste sapphapete sünteesi häired, sealhulgas sterool 27-hüdroksülaasi (avaldub tserebrotendinoosse ksantomatoosina) puudulikkus (n = 4).
Of these 41 patients, 29 presented with disorders in primary bile acid synthesis including Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency (n=4).
Neist 41 patsiendist 29-l olid esmaste sapphapete sünteesi häired, sealhulgas: sterool 27-hüdroksülaasi (avaldub tserebrotendinoosse ksantomatoosina) puudulikkus (n = 4).
Of these 6,684 were treated with 150 mg or 220 mg daily of Pradaxa.
Neist 6 684 patsienti said ööpäevas 150 mg või 220 mg Pradaxa’t.
Of these 7 patients,3 had eye, 1 had sinus, and 3 had disseminated infection.
Nimetatud seitsmest haigest kolmel oli tegemist silma, ühel siinuse ja kolmel dissemineerunud seeninfektsiooniga.
Of these events, 40.5% in the Stivarga arm and 66.7% in the placebo arm have been reported as not recovered / not resolved.
Stivarga ravirühmas ei paranenud/lahenenud 40,5% neist juhtudest ja platseebo ravirühmas 66,7% juhtudest.
Of these infants, 1,177 were involved in clinical trials in which most received PROCOMVAX concomitantly with other licensed paediatric vaccines.
Neist lastest 1177 osalesid kliinilistes uuringutes, kus enamik lapsi sai PROCOMVAX’i samaaegselt teiste registreeritud laste vaktsiinidega.
Of these patients, 100% (7 out of 7) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
100%-l nendest patsientidest (7 patsienti 7-st) mobiliseeris CD34+ rakke ≥ 2 x106/kg ja siirdamine oli nende puhul edukas.
Of these patients, 12% achieved a PASI-75 response at Week 52 with apremilast plus topical and/or phototherapy treatment.
Neist patsientidest 12% saavutasid apremilastiga koos paikse ja/või valgusraviga 52. nädalaks PASI-75 ravivastuse.
Of these patients, 211 patients were treated with trametinib for BRAF V600 mutant melanoma in a randomised open label phase III study (see section 5.1).
Nendest patsientidest 211 said trametiniibi BRAF V600 mutantse melanoomi raviks randomiseeritud avatud III faasi uuringus (vt lõik 5.1).
Of these patients, 248 are from the Phase 3 study in previously untreated CML patients, 570 and 52 are from two Phase 1/2 studies in previously treated Ph+ leukaemias.
Neist patsientidest 248 on III faasi uuringust, kes saavad esimest korda KML-i ravi, 570 ja 52 on I/II faasi uuringutest varem ravitud Ph+ leukeemiaga.
Of these patients, 55 % (34 out of 62) mobilised ≥ 2 x106/kg CD34+ cells and had successful engraftment.
55% nendest patsientidest (34 patsienti 62-st) mobiliseeris CD34+ rakke ≥ 2 x 106/kg ja siirdamine oli nende puhul edukas.
Of these patients, 55/57 (96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a ≥ 1- point decrease in Ishak fibrosis score.
Nendest patsientidest 55/57 (96%) esines histoloogiline paranemine vastavalt varasemale määratlusele (vt ülalpool) ja 50/57 (88%) patsiendil oli ≥ 1-punktiline vähenemine Ishak'i fibroosi skooris.
Of these patients, 84% experienced adverse events and 15% experienced serious adverse events.
Neist patsientidest 84%-l tekkisid kõrvaltoimed ja 15%-l tõsised kõrvaltoimed.
Of these patients, 87% of (151 out of 173) had 30% reduction in the number and severity of symptoms after 16 weeks.
Neist 87%-l (151 patsienti 173st) vähenes sümptomite arv ja raskus 16 nädala järel 30%.
Of these patients, 892 patients received linaclotide at the recommended dose of 290 micrograms per day.
Neist patsientidest sai 892 isikut linaklotiidi soovitatavas annuses 290 mikrogrammi päevas.
Of these patients, most were adolescent or young adult males and most had either Crohn’s disease or ulcerative colitis.
Enamik nendest patsientidest olid noorukid või noored meessoost täiskasvanud ning enamikul neist oli Crohni tõbi või haavandiline koliit.
Of these patients, most were adolescent or young adult males and most had either Crohn’s disease or ulcerative colitis.
Enamik nendest patsientidest olid noorukid või noored meessoost täiskasvanud ning suuremal osal nendest esines Crohni tõbi või haavandiline koliit.
Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.4 (1.0, 5.7) per 1000 patient-years among Trudexa-treated patients and 0 per 1000 patient-years among control patients.
Nendest nahavähkidest täheldati lamerakulisi kartsinoome esinemissagedusega (95%-usaldusvahemik) 2,4 juhtu (1,0; 5,7) 1000 patsientaasta kohta Trudexa’t saanud patsientidel ja 0 juhtu 1000 patsientaasta kohta kontrollgrupi patsientidel.
Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7 (1.4, 5.4) per 1,000 patient-years among Humira- treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among control patients.
Nendest nahavähkidest täheldati lamerakulisi kartsinoome esinemissagedusega (95% usaldusvahemik) 2,7 juhtu (1,4; 5,4) 1000 patsientaasta kohta Humira’t saanud patsientidel ja 0,6 (0,1; 4,5) juhtu 1000 patsientaasta kohta kontrollgrupi patsientidel.
Of these studies the main study involved over 2,000 children aged 2 to 17 years who were vaccinated with either Fluenz Tetra or one of two Fluenz vaccines containing either one of the two influenza B strains which are also contained in Fluenz Tetra.
Põhiuuringus osales üle 2000 lapse vanuses 2–17 aastat, kes olid vaktsineeritud kas Fluenz Tetraga või ühega kahest Fluenzi vaktsiinist, mis sisaldasid üht kahest Fluenz Tetras sisalduvast B-gripi tüvest.
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1)
Sellest 3618 osalejale manustati imitatsioonvaktsiini Foclivia (A/H5N1) (vt lõik 5.1).
Of these subjects, 3618 subjects received the mock-up vaccine Foclivia (A/H5N1) (see section 5.1).
Sellest 3618 osalejale manustati imitatsioonvaktsiini Foclivia (A/H5N1) (vt lõik 5.1).
Of these, 1,139 were ≥ 65 years of which 115 were ≥ 75 years.
Nendest 1139 olid ≥ 65-aastased, kellest 115 olid ≥ 75-aastased.
Of these, 3 patients achieved complete remission (27%), 1 patient had partial remission (9%), 1 patient had haematologic improvement (9%) and 2 patients had therapeutic efficacy (18%).
Neist 3 patsiendi puhul saavutati täielik remissioon (27%), 1 patsiendil oli osaline remissioon (9%), 1 patsiendil oli hematoloogiline paranemine (9%) ja 2 patsiendi puhul oli näha ravitoimet (18%).
Of these, 3,671 patients were exposed to Cosentyx for at least one year, representing 6,450 patient years of exposure.
Nendest 3671 patsienti said Cosentyx-ravi vähemalt ühe aasta, mis annab ravimise ajaks 6450 patsiendiaastat.
Of these, 342 patients had RAS wild-type tumours while RAS mutations were identified in 65 patients.
Nendest 342-l patsiendil olid metsikut tüüpi RAS-kasvajad, RAS-i mutatsioonid tuvastati aga 65-l patsiendil.
Of these, 427 completed 2 years of open- label follow-up and thus had a total exposure to Cimzia of 148 weeks overall.
Kaks aastat kestnud avatud jätku-uuring viidi läbi 427 patsiendiga ja nad said kokku 148 nädalat Cimzia-ravi.
Of these, 45 went on to a fourth, long-term study looking at the effectiveness of Mimpara over a total of almost six years.
Neist patsientidest 45 osales neljandas, pikaajalises uuringus, milles vaadeldi Mimpara toime efektiivsust kokku ligikaudu kuue aasta jooksul.
Of these, 49 % of orlistat treated patients and 40 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Neist 49%-l orlistati ja 40%-l platseebot saanud patsientidest oli ühe aasta möödudes kehakaal vähenenud 10% algväärtusest.
Of these, 5.1% were mild and 1.0% were moderate and 0.1% were classified as severe.
Neist juhtudest 5,1% olid kerged ja 1,0% mõõdukad ja 0,1% loeti raskeks.
Of these, 62 % of orlistat treated patients and 52 % of placebo treated patients went on to lose ≥ 10 % of their baseline body weight at one year.
Neist 62%-l orlistati ja 52%-l platseebot saanud patsientidest oli ühe aasta möödudes kehakaal vähenenud 10% algväärtusest.
Of these, 900 patients patients have been treated for one year or longer.
Nendest 900 on ravi saanud aasta või kauem.
Of these, grade 3 was common, grade 4 uncommon.
Nendest 3. raskusastme infektsioone tekkis sageli ja 4. raskusastme infektsioone aeg-ajalt.
Of those cases 20 reported paraesthesia within one to three days of vaccination, including 17 cases where paraesthesia was the primary symptom.
Neist 20 juhul teatati paresteesiast ühe kuni kolme päeva jooksul pärast vaktsineerimist, sh 17 patsiendil oli paresteesia esmane sümptom.
Of those forty-three (43) patients, two(2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol.
Neist 43 patsiendist katkestasid kaks (2) õde-venda uuringu pärast esimest ristuvat perioodi neist ühe (1) plaanilise operatsiooni tõttu ning uuringuprotokollis ettenähtud protseduurid läbisid 41 patsienti.
Of those in clinical response at week 4, 48% had been previously exposed to other anti-TNF therapy.
Nendest, kellel ilmnes ravivastus 4. nädalaks, olid 48% eelnevalt saanud teist anti- TNF ravi.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
Nendest, kellel ilmnes ravivastus 4. nädalaks, olid 48% eelnevalt saanud muud TNF-antagonisti.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
Nendest, kellel ilmnes ravivastus 4. nädalaks, olid 48% eelnevalt saanud teist TNF-antagonisti.
Of those patients who had infusion related reactions, those dosed with vedolizumab had more infusion related reactions with in the first two hours as compared to placebo patients with infusion related reactions.
Patsientidest, kellel täheldati infusiooniga seotud reaktsioone, esines vedolizumabiga ravitud patsientidel platseebot saanud patsientidega võrreldes infusiooniga seotud reaktsioone rohkem esimese kahe tunni jooksul.